热门资讯> 正文
Avidity Biosciences定价6亿美元股票发行
2025-09-12 12:43
- Avidity Biosciences (NASDAQ:RNA) has priced an upsized offering of 15M shares at $40 each to raise gross proceeds of $600M.
- In addition, the biopharmaceutical company has granted the underwriters a 30-day option to purchase up to an additional 2.25M shares. The offering is expected to close on or about September 15, 2025, subject to the satisfaction of customary closing conditions.
- Proceeds, together with its existing cash, will be used to advance the development of its three late-stage clinical programs, to build appropriate commercial inventory levels to support multiple potential launches, to expand its commercial infrastructure, to progress R&D associated with its AOC platform, and for working capital and general corporate purposes.
- Source: Press Release
More on Avidity Biosciences
- Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota
- Avidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript)
- Redefining the Treatment of Duchenne Muscular Dystrophy Presentation
- Avidity Biosciences reports data from DMD treatment trials
- Avidity Biosciences launches $500M proposed public offering
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
